Electrochemical Detection of Prostate Cancer Biomarker PCA3 Using Specific RNA-Based Aptamer Labelled with Ferrocene
Open Access
- 24 March 2021
- journal article
- research article
- Published by MDPI AG in Chemosensors
- Vol. 9 (4) , 59
Abstract
This paper reports on a feasibility study of electrochemical in-vitro detection of prostate cancer biomarker PCA3 (prostate cancer antigen 3) in direct assay with specific RNA aptamer labelled with a redox group (ferrocene) and immobilized on a screen-printed gold electrode surface. The cyclic voltammograms and electrochemical impedance spectroscopy methods yield encouraging results on the detection of PCA3 in a range of concentrations from 1 μg/mL down to 0.1 ng/mL in buffer solutions. Both anodic and cathodic current values in cyclic voltammograms measurements and charge transfer resistance values in electrochemical impedance spectroscopy experiments correlate with the PCA3 concentration in the sample. Kinetics studies of the binding of the PCA3 to our aptamer demonstrated high specificity of the reaction with a characteristic affinity constant of approximately molar. The results of this work provide a background for the future development of novel, highly sensitive and cost-effective diagnostic methodologies for prostate cancer detection.
Keywords
This publication has 49 references indexed in Scilit:
- Aptamers: A Promising Tool for Ochratoxin A Detection in Food AnalysisToxins, 2013
- International Variation in Prostate Cancer Incidence and Mortality RatesEuropean Urology, 2012
- Use of PCA3 in detecting prostate cancer in initial and repeat prostate biopsy patientsThe Prostate, 2012
- A Review on the Clinical Utility of PSA in Cancer ProstateIndian Journal of Surgical Oncology, 2012
- Selection and analytical applications of aptamers binding microbial pathogensTrAC Trends in Analytical Chemistry, 2011
- Detection of low molecular weight toxins using an optical phase method of ellipsometrySensors and Actuators B: Chemical, 2011
- PCA3 molecular urine assay for prostate cancer: association with pathologic features and impact of collection protocolsWorld Journal of Urology, 2010
- Label-free biomarker detection from whole bloodNature Nanotechnology, 2009
- Exclusion of inflammation in the differential diagnosis of an elevated prostate-specific antigen (PSA)Urologic Oncology: Seminars and Original Investigations, 2009
- Use of multiple biomarkers for a molecular diagnosis of prostate cancerInternational Journal of Cancer, 2004